BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 9010723)

  • 1. The complexities of T-cell co-stimulation: CD28 and beyond.
    Sperling AI; Bluestone JA
    Immunol Rev; 1996 Oct; 153():155-82. PubMed ID: 9010723
    [No Abstract]   [Full Text] [Related]  

  • 2. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
    van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
    Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of CTLA-4 in the regulation and initiation of T-cell responses.
    Chambers CA; Krummel MF; Boitel B; Hurwitz A; Sullivan TJ; Fournier S; Cassell D; Brunner M; Allison JP
    Immunol Rev; 1996 Oct; 153():27-46. PubMed ID: 9010718
    [No Abstract]   [Full Text] [Related]  

  • 4. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
    Linsley PS; Ledbetter J; Peach R; Bajorath J
    Res Immunol; 1995; 146(3):130-40. PubMed ID: 8525042
    [No Abstract]   [Full Text] [Related]  

  • 5. Could expression of co-stimulatory molecules on B-PBL condition the acceptance or rejection of human liver grafts?
    Minguela A; Sánchez-Bueno F; Marín L; Miras M; Pons JA; Muro M; Torío A; García-Alonso AM; Robles R; Parrilla P; Ramirez P; Alvarez-López MR
    Transplant Proc; 2001; 33(1-2):1384-5. PubMed ID: 11267338
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of autoimmunity by inhibition of T cell costimulation.
    Daikh DI; Wofsy D
    Adv Exp Med Biol; 2001; 490():113-7. PubMed ID: 11505969
    [No Abstract]   [Full Text] [Related]  

  • 7. CTLA-4 and T cell activation.
    Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
    Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New protein steals the show as 'costimulator' of T cells.
    Cohen J
    Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
    Lane P
    Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD28 function: a balance of costimulatory and regulatory signals.
    Bour-Jordan H; Blueston JA
    J Clin Immunol; 2002 Jan; 22(1):1-7. PubMed ID: 11958588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.
    Boussiotis VA; Freeman GJ; Gribben JG; Nadler LM
    Immunol Rev; 1996 Oct; 153():5-26. PubMed ID: 9010717
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses.
    Hathcock KS; Hodes RJ
    Adv Immunol; 1996; 62():131-66. PubMed ID: 8781268
    [No Abstract]   [Full Text] [Related]  

  • 14. Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-H gamma 1 transgenic mice.
    Lane P
    Res Immunol; 1995; 146(3):176-9. PubMed ID: 8525050
    [No Abstract]   [Full Text] [Related]  

  • 15. New molecules on dendritic cells and their interactions with T lymphocytes.
    Hart DN; Starling GC; Egner W; Hock BD; McLellan AD; McKenzie JL; Williams LA; Simmons DL
    Adv Exp Med Biol; 1995; 378():351-4. PubMed ID: 8526091
    [No Abstract]   [Full Text] [Related]  

  • 16. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
    Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
    Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
    Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
    Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.
    Metzler WJ; Bajorath J; Fenderson W; Shaw SY; Constantine KL; Naemura J; Leytze G; Peach RJ; Lavoie TB; Mueller L; Linsley PS
    Nat Struct Biol; 1997 Jul; 4(7):527-31. PubMed ID: 9228944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human inducible costimulator ligand expression and function.
    Aicher A; Hayden-Ledbetter M; Brady WA; Pezzutto A; Richter G; Magaletti D; Buckwalter S; Ledbetter JA; Clark EA
    J Immunol; 2000 May; 164(9):4689-96. PubMed ID: 10779774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
    Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
    Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.